Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease.

Jose A, King CS, Shlobin OA, Brown AW, Wang C, Nathan SD.

Eur Respir J. 2018 Sep 27;52(3). pii: 1801015. doi: 10.1183/13993003.01015-2018. Print 2018 Sep. No abstract available.

PMID:
30093570
2.

Critical Care of the Adult Patient With Cystic Fibrosis.

King CS, Brown AW, Aryal S, Ahmad K, Donaldson S.

Chest. 2018 Aug 2. pii: S0012-3692(18)31123-1. doi: 10.1016/j.chest.2018.07.025. [Epub ahead of print] Review.

PMID:
30077689
3.

Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia.

King CS, Brown AW, Shlobin OA, Weir N, Libre M, Franco-Palacios D, Ahmad S, Nathan SD.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800545. doi: 10.1183/13993003.00545-2018. Print 2018 Jul. No abstract available.

PMID:
29773690
4.

A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation.

Warren WA, Franco-Palacios D, King CS, Shlobin OA, Nathan SD, Katugaha SB, Mani H, Brown AW.

Chest. 2018 Mar;153(3):e53-e56. doi: 10.1016/j.chest.2017.08.020.

PMID:
29519311
5.

A 70-Year-Old Woman Presenting With Diarrhea and In-hospital Cardiac Arrest.

Jose A, Franco-Palacios D, King CS, Gomberg-Maitland M.

Chest. 2018 Jan;153(1):e5-e8. doi: 10.1016/j.chest.2017.07.042. No abstract available.

PMID:
29307435
6.

Cardiac Support: Emphasis on Venoarterial ECMO.

King CS, Roy A, Ryan L, Singh R.

Crit Care Clin. 2017 Oct;33(4):777-794. doi: 10.1016/j.ccc.2017.06.002. Epub 2017 Jul 21. Review.

PMID:
28887927
7.

IRB Problems and Solutions in Health Communication Research.

King CST, Bivens KM, Pumroy E, Rauch S, Koerber A.

Health Commun. 2018 Jul;33(7):907-916. doi: 10.1080/10410236.2017.1321164. Epub 2017 Jun 6.

PMID:
28586270
8.

Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension.

Jose A, King CS, Shlobin OA, Kiernan JM, Cossa NA, Brown AW, Nathan SD.

Chest. 2017 Nov;152(5):980-989. doi: 10.1016/j.chest.2017.05.008. Epub 2017 May 17.

PMID:
28527879
9.

Early postoperative management after lung transplantation: Results of an international survey.

King CS, Valentine V, Cattamanchi A, Franco-Palacios D, Shlobin OA, Brown AW, Singh R, Bogar L, Nathan SD.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12985. Epub 2017 May 29.

PMID:
28425132
10.

Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality.

Hong A, King CS, Brown AW, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Rongione A, Nathan SD.

Multidiscip Respir Med. 2016 Nov 15;11:40. eCollection 2016.

11.

Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.

King CS, Nathan SD.

Lancet Respir Med. 2017 Jan;5(1):72-84. doi: 10.1016/S2213-2600(16)30222-3. Epub 2016 Sep 3. Review.

PMID:
27599614
12.

The impact of early de novo donor-specific antibodies on lung transplant outcomes: Is timing everything?

King CS, Cochrane AB.

J Heart Lung Transplant. 2016 Sep;35(9):1057-8. doi: 10.1016/j.healun.2016.07.003. Epub 2016 Jul 16. No abstract available.

PMID:
27578598
13.

Rebuttal From Drs King and Nathan.

King CS, Nathan SD.

Chest. 2016 Aug;150(2):278. doi: 10.1016/j.chest.2016.04.035. Epub 2016 Jun 9. No abstract available.

PMID:
27292048
14.

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.

King CS, Nathan SD.

Chest. 2016 Aug;150(2):273-5. doi: 10.1016/j.chest.2016.04.034. Epub 2016 Jun 9. No abstract available.

PMID:
27292047
15.

Introducing routine HIV screening for patients on an internal medicine residency inpatient service: a quality improvement project.

Padrnos LJ, Barr PJ, Klassen CL, Fields HE, Azadeh N, Mendoza N, Saadiq RA, Pauwels EM, King CS, Chung AA, Sakata KK, Blair JE.

BMJ Qual Improv Rep. 2016 May 5;5(1). pii: u206955.w3030. doi: 10.1136/bmjquality.u206955.w3030. eCollection 2016.

16.

The developmental biogeography of hawksbill sea turtles in the North Pacific.

Van Houtan KS, Francke DL, Alessi S, Jones TT, Martin SL, Kurpita L, King CS, Baird RW.

Ecol Evol. 2016 Mar 8;6(8):2378-89. doi: 10.1002/ece3.2034. eCollection 2016 Apr.

17.

Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L.

Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7. Erratum in: Chest. 2016 Oct;150(4):988.

PMID:
26867832
18.

Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis.

Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SD.

Eur Respir J. 2016 May;47(5):1445-51. doi: 10.1183/13993003.01532-2015. Epub 2016 Feb 4.

19.

Organ Donors: Making the Most of What Is Offered.

Nathan SD, King CS.

Chest. 2015 Aug;148(2):303-305. doi: 10.1378/chest.15-1269. No abstract available.

PMID:
26238828
20.

Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.

King CS, Nathan SD.

Curr Opin Pulm Med. 2015 Sep;21(5):479-89. doi: 10.1097/MCP.0000000000000190. Review.

PMID:
26164298
21.

Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease.

Shin S, King CS, Brown AW, Albano MC, Atkins M, Sheridan MJ, Ahmad S, Newton KM, Weir N, Shlobin OA, Nathan SD.

Respir Med. 2014 Nov;108(11):1626-32. doi: 10.1016/j.rmed.2014.08.009. Epub 2014 Sep 2.

22.

Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

Nathan SD, King CS.

Drug Des Devel Ther. 2014 Jul 2;8:875-85. doi: 10.2147/DDDT.S64907. eCollection 2014. Review.

23.

Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.

King CS, Holley AB, Moores LK.

Chest. 2013 Apr;143(4):1106-1116. doi: 10.1378/chest.12-1362. Review.

PMID:
23546483
24.

Severe cavitary pneumonia caused by a non-equi Rhodococcus species in an immunocompetent patient.

Ng S, King CS, Hang J, Clifford R, Lesho EP, Kuschner RA, Cox ED, Stelsel R, Mody R.

Respir Care. 2013 Apr;58(4):e47-50. doi: 10.4187/respcare.02017. No abstract available.

25.

Eucapnic voluntary hyperventilation is superior to methacholine challenge testing for detecting airway hyperreactivity in nonathletes.

Holley AB, Cohee B, Walter RJ, Shah AA, King CS, Roop S.

J Asthma. 2012 Aug;49(6):614-9. doi: 10.3109/02770903.2012.697955.

PMID:
22793526
26.

A 26-year-old woman with a lump in her chest.

Wagler VD, Huitron S, King CS.

Cleve Clin J Med. 2012 Mar;79(3):177-8. doi: 10.3949/ccjm.79a.11070. No abstract available.

PMID:
22383551
27.

Current approach to the diagnosis of acute nonmassive pulmonary embolism.

Moores LK, King CS, Holley AB.

Chest. 2011 Aug;140(2):509-518. doi: 10.1378/chest.10-2468.

PMID:
21813530
28.

Human handling promotes compliant behavior in adult laboratory rabbits.

Swennes AG, Alworth LC, Harvey SB, Jones CA, King CS, Crowell-Davis SL.

J Am Assoc Lab Anim Sci. 2011 Jan;50(1):41-5.

29.

High-grade primary pulmonary B cell lymphoma presenting as a necrotic mass.

Brown S, Horton J, Rosario D, Dorsey DA, Hetz S, King CS.

Respir Care. 2011 Jun;56(6):871-3. doi: 10.4187/respcare.01003. Epub 2011 Feb 11. No abstract available.

30.

A 29-year-old female at 33 weeks' gestation with respiratory failure.

Gayle RB, Dorsey DA, Cole MA, King CS.

Chest. 2010 Jun;137(6):1474-8. doi: 10.1378/chest.09-2860. No abstract available.

PMID:
20525660
31.

Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis.

Holley AB, King CS, Jackson JL, Moores LK.

Thrombosis. 2010;2010:540386. doi: 10.1155/2010/540386. Epub 2010 Dec 29.

32.

Should patients be able to follow commands prior to extubation?

King CS, Moores LK, Epstein SK.

Respir Care. 2010 Jan;55(1):56-65. Review.

33.

Treatment of sarcoidosis.

King CS, Kelly W.

Dis Mon. 2009 Nov;55(11):704-18. doi: 10.1016/j.disamonth.2009.06.002. Review. No abstract available.

PMID:
19857644
34.

A Multilayer MEMS Platform for Single-Cell Electric Impedance Spectroscopy and Electrochemical Analysis.

Dittami GM, Ayliffe HE, King CS, Rabbitt RD.

J Microelectromech Syst. 2008 Aug 1;17(4):850-862.

35.

Multiple pulmonary nodules in a 70-year-old female with a history of breast cancer.

Gambino SL, King CS, Lettieri CJ.

Chest. 2009 Sep;136(3):938-941. doi: 10.1378/chest.08-2994. No abstract available.

PMID:
19736199
36.

Native lung complications in single-lung transplant recipients and the role of pneumonectomy.

King CS, Khandhar S, Burton N, Shlobin OA, Ahmad S, Lefrak E, Barnett SD, Nathan SD.

J Heart Lung Transplant. 2009 Aug;28(8):851-6. doi: 10.1016/j.healun.2009.04.023.

PMID:
19632585
37.

Clinical and lung-function variables associated with vocal cord dysfunction.

Watson MA, King CS, Holley AB, Greenburg DL, Mikita JA.

Respir Care. 2009 Apr;54(4):467-73.

38.

Discordance in spirometric interpretations using three commonly used reference equations vs national health and nutrition examination study III.

Collen J, Greenburg D, Holley A, King CS, Hnatiuk O.

Chest. 2008 Nov;134(5):1009-1016. doi: 10.1378/chest.08-0614.

PMID:
18988777
39.

Severe bullous lung disease due to marginal-zone-lymphoma-associated amyloidosis.

King CS, Holley AB, Sherner JH.

Respir Care. 2008 Nov;53(11):1495-8. No abstract available.

40.

Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy.

Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG.

Thyroid. 2008 Sep;18(9):983-8. doi: 10.1089/thy.2007.0404. Review.

41.

Clinical asthma syndromes and important asthma mimics.

King CS, Moores LK.

Respir Care. 2008 May;53(5):568-80; discussion 580-2. Review.

42.

Anisotropic magnetoresistance components in (Ga,Mn)As.

Rushforth AW, Výborný K, King CS, Edmonds KW, Campion RP, Foxon CT, Wunderlich J, Irvine AC, Vasek P, Novák V, Olejník K, Sinova J, Jungwirth T, Gallagher BL.

Phys Rev Lett. 2007 Oct 5;99(14):147207. Epub 2007 Oct 3.

PMID:
17930718
43.

Bilateral parotitis and facial nerve palsy.

King CS, Zapor M.

Cleve Clin J Med. 2007 Jul;74(7):512-3. No abstract available.

PMID:
17682628
44.

Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis.

King CS, Holley AB, Jackson JL, Shorr AF, Moores LK.

Chest. 2007 Feb;131(2):507-16.

PMID:
17296655
45.

Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts.

Gianoukakis AG, Jennings TA, King CS, Sheehan CE, Hoa N, Heldin P, Smith TJ.

Endocrinology. 2007 Jan;148(1):54-62. Epub 2006 Oct 26.

PMID:
17068136
46.
47.

Rhabdomyosarcoma Associated With Incisor Malocclusion in a Laboratory Rat.

Brockus CW, Rakich PM, King CS, Broderson JR.

Contemp Top Lab Anim Sci. 1999 Nov;38(6):42-43. No abstract available.

PMID:
12086448
48.

Activation of PTHrP gene expression in squamous carcinoma cell lines by mutant isoforms of the tumor suppressor p53.

Foley J, King CS, Jiménez JA, Wysolmerski JJ, Philbrick WM.

Oncol Res. 2000;12(2):71-81.

PMID:
11132926
49.

Regulation of parathyroid hormone-related protein gene expression in murine keratinocytes by E1A isoforms: a role for basal promoter and Ets-1 site.

Foley J, Wysolmerski JJ, Missero C, King CS, Philbrick WM.

Mol Cell Endocrinol. 1999 Oct 25;156(1-2):13-23.

PMID:
10612419
50.

Choose a path.

King CS.

Adv Pract Nurs Q. 1997 Spring;2(4):7-8.

PMID:
9447098

Supplemental Content

Support Center